Investigators found hepatic lipocalin 2 (LCN2) expression and serum LCN2 level markedly increased and correlated with disease severity and portal hypertension in patients with alcoholic hepatitis.
[Scientific Reports]
0
Category Archives: Hepatic Cell
Hepatic Cell NewsHepatic Cell News is an online publication and email newsletter covering the top research on hepatocytes and liver diseases.
The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. The newsletter covers areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!
Hepatic Lipocalin 2 Promotes Liver Fibrosis and Portal Hypertension
Understanding Lipotoxicity in NAFLD Pathogenesis: Is CD36 a Key Driver?
Investigators provide succinct insights into the molecular mechanisms responsible for lipotoxicity in non-alcoholic fatty liver disease (NAFLD), including ER and oxidative stress, autophagy, lipoapotosis and inflammation. They highlight the role of CD36/FAT fatty acid translocase in NAFLD pathogenesis.
[Cell Death & Disease]
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020). Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death & Disease, 11(9), 1–15. https://doi.org/10.1038/s41419-020-03003-w Cite
0
Controversies Surrounding the Origin of Hepatocytes in Adult Livers and the In Vitro Generation or Propagation of Hepatocytes
The authors highlight how insights into hepatocyte regeneration and biology in vivo can inform in vitro studies to propagate primary hepatocytes with signals in liver regeneration and to generate hepatocytes de novo from pluripotent stem cells.
[Cellular and Molecular Gastroenterology and Hepatology]
Qian Pek, N. M., Liu, K. J., Nichane, M., & Ang, L. T. (2020). Controversies surrounding the origin of hepatocytes in adult livers and the in vitro generation or propagation of hepatocytes. Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2020.09.016 Cite
0
Aberrant NSUN2-Mediated m5C Modification of H19 lncRNA Is Associated with Poor Differentiation of Hepatocellular Carcinoma
In this study, scientists knocked down the NSUN2 gene in HepG2 cells by CRISPR/Cas9 technology and performed high-throughput RNA-BisSeq. An important tumor-related lncRNA H19 was identified to be targeted by NSUN2.
[Oncogene]
Sun, Z., Xue, S., Zhang, M., Xu, H., Hu, X., Chen, S., Liu, Y., Guo, M., & Cui, H. (2020). Aberrant NSUN2-mediated m 5 C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01475-w Cite
0
Overexpressed sFRP3 Exerts an Inhibitory Effect on Hepatocellular Carcinoma via Inactivation of the Wnt/β-Catenin Signaling Pathway
Researchers investigated the possible regulatory effects of a secreted frizzled-related protein (sFRP3) on the Wnt/β-catenin signaling pathway and their interactions in hepatocellular carcinoma occurrence.
[Cancer Gene Therapy]
Fang, L., Gao, C., Bai, R.-X., Wang, H.-F., & Du, S.-Y. (2020). Overexpressed sFRP3 exerts an inhibitory effect on hepatocellular carcinoma via inactivation of the Wnt/β-catenin signaling pathway. Cancer Gene Therapy, 1–17. https://doi.org/10.1038/s41417-020-0201-z Cite
0
DCLK1, a Putative Novel Stem Cell Marker in Human Cholangiocarcinoma
Investigators evaluated in vitro the expression and the biological function of DCLK1 in intrahepatic cholangiocarcinom (CCA) and perihilar CCA.
[Hepatology]
Nevi, L., Matteo, S. D., Carpino, G., Zizzari, I., Safarikia, S., Ambrosino, V., Costantini, D., Overi, D., Giancotti, A., Monti, M., Bosco, D., Peppo, V. D., Oddi, A., Rose, A. M. D., Melandro, F., Bragazzi, M. C., Faccioli, J., Massironi, S., Grazi, G. L., … Alvaro, D. (n.d.). DCLK1, a putative novel stem cell marker in human cholangiocarcinoma. Hepatology, n/a(n/a). https://doi.org/10.1002/hep.31571 Cite
0
Onco-Fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma
The hepatocellular carcinoma ecosystem displayed features reminiscent of fetal development, including re-emergence of fetal-associated endothelial cells and fetal-like tumor-associated macrophages.
[Cell]
Sharma, A., Seow, J. J. W., Dutertre, C.-A., Pai, R., Blériot, C., Mishra, A., Wong, R. M. M., Singh, G. S. N., Sudhagar, S., Khalilnezhad, S., Erdal, S., Teo, H. M., Khalilnezhad, A., Chakarov, S., Lim, T. K. H., Fui, A. C. Y., Chieh, A. K. W., Chung, C. P., Bonney, G. K., … DasGupta, R. (2020). Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 0(0). https://doi.org/10.1016/j.cell.2020.08.040 Cite
0
PTEN Status Determines Chemosensitivity to Proteasome Inhibition in Cholangiocarcinoma
Scientists determined that phosphate and tensin homology deleted on chromosome ten (PTEN) deficiency promoted protein synthesis and proteasome subunit expression and proteolytic activity, creating a dependency on the proteasome for cancer cell growth and survival.
[Science Translational Medicine]
0
A Novel β2-AR/YB-1/β-Catenin Axis Mediates Chronic Stress-Associated Metastasis in Hepatocellular Carcinoma
Investigators performed immunoprecipitation-mass spectrometry analysis of hepatocellular carcinoma (HCC) tissues. A vital oncoprotein, Y-box binding protein 1 (YB-1), was shown to interact with β2-adrenergic receptor (β2-AR) in HCC cells.
[Oncogenesis]
0
T. Gondii Infection Induces Il-1R Dependent Chronic Cachexia and Perivascular Fibrosis in the Liver and Skeletal Muscle
IL-1α was sufficient to activate cultured fibroblasts and primary hepatic stellate cells in vitro, and IL-1α was elevated in the sera and liver of cachectic, suggesting a mechanism by which chronic IL-1R signaling could be leading to cachexia-associated fibrosis.
[Scientific Reports]
0
GENFIT Announces First Patient First Visit for ELATIVE Phase III Study Evaluating Elafibranor in PBC
GENFIT are a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases. They have announced the first patient first visit for ELATIVE, the global, pivotal, Phase III study evaluating elafibranor in Primary Biliary Cholangitis (PBC).
[GENFIT]
0
